To specifically test for the potential re-gain of apoptotic competency in AD iNs, we exposed iNs to the Bcl2-inhibitor ABT-737, a pro-apoptotic stimulant, and initially monitored a dose-dependent increase in the proportion of cells positive for Casp3 (Figures 6C and 6D). This evidence concerns the gene BCL2 and Alzheimer disease.